KAD84051
Colorimetric
Plasma, Serum
Quantitative
15.625-1,000 ng/ml
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CNTO 1275, TT-20, CAS: 815610-63-0
New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects., PMID:39300815
A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris., PMID:38962596
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence., PMID:38499168
Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study., PMID:38174886
The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate., PMID:37079726
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial., PMID:36417156
Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose., PMID:36066279
Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease., PMID:35223697
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies., PMID:34960217
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition., PMID:33626969
Hard-to-treat psoriasis in a child developing neutralizing anti-drug antibodies against adalimumab during Streptococcus pyogenes throat infection: a case report., PMID:33348943
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus., PMID:33010188
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study., PMID:32283057
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis., PMID:32069329
Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report., PMID:31488067
IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans., PMID:31470035
Are new variants of psoriasis therapy (IL-17 inhibitors) safe?, PMID:31192456
Immunogenicity and skin clearance recapture in clinical studies of brodalumab., PMID:31175910
Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab., PMID:30656642
Targeted therapies for pediatric psoriasis., PMID:30215634
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review., PMID:28612180
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study., PMID:28602039
Managing refractory Crohn's disease: challenges and solutions., PMID:25914555
Monomeric IgA can be produced in planta as efficient as IgG, yet receives different N-glycans., PMID:25196296
Anti-IL-12/23 in Crohn's disease: bench and bedside., PMID:24138637
Antidrug antibodies in psoriasis: a systematic review., PMID:24117166
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases., PMID:22280236
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?, PMID:19271940
Th17 cells: a new therapeutic target in inflammatory dermatoses., PMID:18626814
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
